This study hypothesizes that electroacupuncture combined with self-administered acupressure plus doctor-prescribed treatment is effective in preventing Hand-Foot Syndrome (HFS) caused by capecitabine. It aims to explore the effectiveness of this combined approach in preventing HFS in patients with malignant tumors undergoing oral capecitabine treatment. Further exploration of prevention and treatment methods may enhance the quality of life for patients during the treatment process.
Sign a written informed consent form;
Male or female ≥ 18 years old;
Patients with gastrointestinal cancer or breast cancer who are diagnosed with cancer by pathology will receive capecitabine treatment for the first time according to the label;
The performance status of the Eastern Cancer Collaboration Group is 0-2;
Previous use of capecitabine or liposome doxorubicin or any other tyrosine kinase inhibitor that may induce HFS (such as sorafenib, sunitinib, and apatinib) for chemotherapy;
The initial dose of capecitabine is less than 800mg/m²;
Radiation therapy or surgery should be performed within 4 weeks before the start of treatment;
Skin diseases that may interfere with clinical trial results;